Former uniQure and Evotec CEO pushes new viral candidate into Clinical Trials

21/07/2016 - 2 minutes

Hookipa is starting its first clinical trial for a vaccine against human cytomegalovirus. This is the leading candidate of its platform for novel viral vectors, which promises to yield better vaccines for infections and cancer.

hookipa vaccine vaxwave hb-101 hcmvBased in Vienna, Hookipa was founded in 2011 and is developing a new class of immunotherapies. Its strategy for novel viral vectors already attracted €27M from top Biotech investors in Europe like Sofinnova and Forbion.

Just last month, the Biotech also appointed new CEO – Joern Aldag, a Biotech veteran who we recently interviewed about his really successful career. Hookipa is keeping its momentum, now beginning its first clinical trial.

The trial is a Phase I study to assess the safety of the Biotech’s leading candidate, the HB-101 vaccine for the prevention of human cytomegalovirus (hCMV). This virus is one of the most significant infections for immunocompromised patients and during pregnancy. As hCMV is still without a vaccine, it has been ranked at the highest priority by health authorities.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member